Curis Lifesciences IPO Details
The key details of Curis Lifesciences’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹27.52 Cr |
| Price Range | ₹120 - ₹128 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE |
| Minimum Quantity | 2,000 |
| Investment (cut-off price) | ₹2,56,000 |
| Pre IPO Promotor Holding | 92.68% |
| Post IPO Promotor Holding | 68.03% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Curis Lifesciences IPO Timelines
The IPO process for Curis Lifesciences includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
07/11/2025
Start Date11/11/2025
End Date13/11/2025
Refund Initiation13/11/2025
Credit of Shares to Demat Ac14/11/2025
Listing DateCuris Lifesciences IPO Lot Size
The Curis Lifesciences IPO has a fixed lot size of 1,000 shares, at an upper price band of ₹128 per share. For retail investors, the minimum and maximum application is 2,000 shares (2 lots) amounting to ₹2,56,000. For Small HNI (S-HNI) investors, the minimum application is 3,000 shares (3 lots) worth ₹3,84,000, while the maximum is 7,000 shares (7 lots) amounting to ₹8,96,000. Big HNI (B-HNI) investors need to apply for at least 8,000 shares (8 lots), totaling ₹10,24,000.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 2000 | ₹2,56,000 |
| Retail Maximum | 2 | 2000 | ₹2,56,000 |
| S-HNI Minimum | 3 | 3000 | ₹3,84,000 |
| S-HNI Maximum | 7 | 7000 | ₹8,96,000 |
| B-HNI Minimum | 8 | 8000 | ₹10,24,000 |
Curis Lifesciences IPO Subscription Status
The subscription status for Curis Lifesciences IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
IPO Performance on Listing Day
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹ | ₹ | ₹ | ₹ |
Curis Lifesciences IPO Company Financials
Curis Lifesciences reports robust performance in FY2026 July with Total Income of ₹19.51 crores, managing expenses at ₹15.79 crores, and achieving a strong PAT (Profit After Tax) of ₹2.87 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2023 | ₹36.42 | ₹34.23 | ₹1.88 |
| FY 2024 | ₹35.87 | ₹28.70 | ₹4.87 |
| FY 2025 | ₹49.65 | ₹41.38 | ₹6.11 |
| FY 2026 (4 M) | ₹19.51 | ₹15.79 | ₹2.87 |
About Company
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of healthcare products. The company operates both globally and domestically, offering services on a loan license and contract manufacturing basis, as well as producing pharmaceutical goods for its own brand marketing.
Curis Lifesciences serves over 100 corporate clients through contract manufacturing arrangements and two clients for its own brands in Yemen and Kenya. Its product portfolio includes general pharmaceutical tablets and capsules, oral liquids, external preparations, and sterile ophthalmic ointments. The company runs a state-of-the-art facility in Sanand, Gujarat, maintaining strict quality control standards to ensure product safety and efficacy. As of July 31, 2025, it employs 95 permanent staff members.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2010 | Pharmaceuticals | Dharmesh Patel |
Know Before Investing
Curis Lifesciences IPO Strengths
- The company offers a wide range of pharmaceutical products, including APIs and formulations catering to multiple therapeutic segments.
- Their plant is located in Gujarat, a key pharmaceutical hub, offering supply chain and regulatory advantages.
- Curis has the capacity to expand production easily to meet growing market demand.
- The company is actively registering products in international markets, expanding export potential.
- The debt-to-equity ratio is moderate, supporting sustainable growth with manageable financial leverage.
Curis Lifesciences IPO Risks
- Pharmaceutical companies face stringent regulatory environments, with changes potentially leading to delays, penalties, or increased costs.
- As a relatively smaller player, Curis faces strong competition from established domestic and international pharmaceutical companies.
- Expanding exports exposes the company to foreign exchange fluctuations and international regulatory challenges.
- Fluctuations in API and raw material prices can impact profit margins.
- Dependence on a few key products could make the company vulnerable to market shifts or new competing drugs.
- Pharmaceutical manufacturing requires significant investment in inventory and receivables, tightening liquidity.
Swot Analysis for Curis Lifesciences IPO
Strengths
Regulatory Compliance, Robust Client Relationships, Multiple Revenue Streams
Weaknesses
Small Workforce, High Client Dependence, Therapeutic Concentration
Opportunities
Emerging Market Expansion, Strategic Partnerships, Growing Pharma Outsourcing
Threats
Strong Industry Competition, Regulatory Evolution, Supply Chain Instability
Company Details
Curis Lifesciences Ltd.
PF-23, GIDC Sanand – II, Industrial Estate, Sanand, Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/
IPO Registar Details
MUFG Intime India Pvt. Ltd.
Phone: +91-22-4918 6270
Email: curislifesciences.smeipo@in.mpms.mufg.com
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
FAQs
The key objectives of Curis Lifesciences SME IPO are:
- Capital Expenditure towards Upgradation/Improvement of the existing Manufacturing Facilities
- Capital Expenditure towards Construction of a Storage Facility
- Pre-payment/Repayment of outstanding Secured Loans
- Product Registrations in other countries
- Funding their Working Capital Requirements
- General Corporate Purposes
Finaax Capital Advisors Private Limited is the book-running lead managers for the Curis Lifesciences IPO.
Curis Lifesciences IPO presents solid growth potential backed by expanding demand for generics, rising exports, and scalable WHO-GMP accredited manufacturing in Ahmedabad. With revenue increasing from ₹36.42 crore in FY23 to ₹49.65 crore in FY25 and strong financial stability, the company is well-positioned for sustainable expansion in the pharmaceutical sector.
The issue price for the Curis Lifesciences IPO is set between ₹120 to ₹128 per share.
To invest in two lot of Curis Lifesciences IPO, you need ₹2,40,000 at the lower price band (₹120 per share) or ₹2,56,000 at the upper price band (₹128 per share) for a lot size of 2000 shares.
Curis Lifesciences IPO shares are scheduled to be listed on the National Stock Exchange (NSE) on November 14, 2025.
Refund/unblocking of funds for Curis Lifesciences IPO will begin on November 13, 2025. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Curis Lifesciences IPO shares on listing day (November 14, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.